Brain implant firm wins 12m with Manchester nanotech – The University of Manchester

A collaboration between two Barcelona institutions and theNanomedicine Labat The University of Manchester- aimed at treating brain disorders such as epilepsy and Parkinsons Disease - has secured 12m in funding, one of the largest investments to date in the European medical nanotechnology industry.

INBRAIN Neuroelectronics is a spin-out company from the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Catalan Institution for Research and Advanced Studies (ICREA), partners of - and supported by - the European Commissions Graphene Flagship programme.

INBRAINs work involves the decoding of brain signals by implantinginnovative, flexible nanoscale graphene electrodes, developed in conjunction with researchers at Manchesters Nanomedicine Laband theNational Graphene Institute(NGI).

These signals may then be used to produce a therapeutic, personalised response for patients with epilepsy, Parkinsons and other neurological disorders.

This new investment is co-led by Barcelona-based venture capitalists Asabys Partners and Alta Life Sciences, joined by: Vsquared Ventures, a deep tech-focused early-stage venture capitalist based in Munich; TruVenturo GmbH, Germanys most successful internet company builders; and CDTI, the Spanish Ministry of Science and Innovation.

Kostas Kostarelos, Professor of Nanomedicine at The University of ManchesterFaculty of Biology, Medicine and Health, the NGI and co-founder of INBRAIN Neuroelectronics, said: This investment for INBRAIN is a testament that graphene-based technologies and the properties of 2D materials have a unique set of propositions to offer for clinical medicine and the management of neurological disorders.

This did not happen suddenly, though, or by a stroke of good luck in the lab, he added. It is the culmination of many years of persistent and consistent work between at least three research institutions, one of which is the Nanomedicine Lab in Manchester, the other two in Barcelona, all working closely and cooperatively under the critically important funding of the Graphene Flagship project.

The Graphene Flagship is the European Commissions 1bn research funding spearhead and a key partner of ICN2, ICREA and Graphene@Manchester, with a mission is to accelerate advanced 2D materials research and commercialisation.

The high incidence of brain-related diseases worldwide and their huge annual cost - around 700bn in Europe alone, according to a 2010 study by the European Brain Council - call for greater investments in basic research in this field, with the aim of developing new and more efficient therapeutic and diagnostic tools.

Existing brain interfaces are based on metals such as platinum and iridium, which significantly restrict miniaturisation and signal resolution, and are therefore responsible for considerable side effects.

As a consequence, there is a 50% rejection rate of these implants in candidate patients. INBRAIN Neuroelectronics has a disruptive technology proposition, based on the novel material graphene, that overcomes the current limitations of metal-based neural interfaces.

Continued here:

Brain implant firm wins 12m with Manchester nanotech - The University of Manchester